Recently, plasma proteins including Aß42 and phosphorylated tau (p-tau217, p-tau181, and others) have been identified as promising plasma biomarkers for clinically and pathologically defined AD [32–34]. This evidence concerns the gene MAPT and Alzheimer disease.